Isomorphic Labs Celebrates US$5bn in Series C Funding

Demis Hassabis, CEO of Isomorphic Labs, says the US$5bn in Series C funding will scale IsoDDE and push AI-designed drug candidates towards clinical trials

Isomorphic Labs Celebrates US$5bn in Series C Funding

TL;DR

  • Isomorphic Labs raised US$5 billion in Series C funding, co-led by Greenoaks and Sequoia Capital.
  • The funding will accelerate the development of its AI drug design engine, IsoDDE.
  • IsoDDE unifies simulation AI models to design molecules with optimal drug-like properties.
  • The company has positive preclinical results in oncology and immunology programs.
  • Key partners include Alphabet, Eli Lilly, and Novartis, with significant collaborations in place.